Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu

M. Kremer, Joel; Blanco, Ricardo; Brzosko, Marek; Burgos‐Vargas, Rubén; Halland, Anne-Marie; Vernon, Emma; Ambs, Petra; Fleischmann, Roy

doi:10.1002/art.30158

Public

Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate: Results from the double-blind treatment phase of a randomized placebo-controlled trial of tocilizumab safety and prevention of structu

Published in Arthritis & Rheumatism • Nov 19, 2010

Authors:

Joel M. Kremer

Ricardo Blanco

Marek Brzosko

Abstract

OBJECTIVE: To assess the efficacy and safety of tocilizumab plus methotrexate (MTX) versus MTX alone in preventing structural joint damage and improving physical function and disease activity in patients with moderate-to-severe rheumatoid arthritis and inadequate responses to MTX. METHODS: A total o...

Subject

Tocilizumab

Medicine

Placebo

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!